Commercial Odyssey eyes $236M for renewed Nasdaq bid, Seaport docks on Nasdaq BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.Read full story pharminent May 4, 2026 BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Celcuity strengthens case for ASCO-spotlighted breast cancer drugNext: Part D Retail Prescription Drugs Related Stories Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026
